-
Je něco špatně v tomto záznamu ?
1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase
S. Krajčovičová, R. Jorda, D. Vanda, M. Soural, V. Kryštof
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Grantová podpora
NV17-31834A
MZ0
CEP - Centrální evidence projektů
- MeSH
- inhibitory proteinkinas farmakologie terapeutické užití MeSH
- lidé MeSH
- nehodgkinský lymfom farmakoterapie MeSH
- proteinkinasa BTK antagonisté a inhibitory MeSH
- pyridiny farmakologie terapeutické užití MeSH
- signální transdukce MeSH
- simulace molekulového dockingu MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019275
- 003
- CZ-PrNML
- 005
- 20210830100844.0
- 007
- ta
- 008
- 210728s2021 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2020.113094 $2 doi
- 035 __
- $a (PubMed)33340912
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Krajčovičová, Soňa $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic
- 245 10
- $a 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase / $c S. Krajčovičová, R. Jorda, D. Vanda, M. Soural, V. Kryštof
- 520 9_
- $a Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.
- 650 _2
- $a proteinkinasa BTK $x antagonisté a inhibitory $7 D000077329
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nehodgkinský lymfom $x farmakoterapie $7 D008228
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
- 650 _2
- $a pyridiny $x farmakologie $x terapeutické užití $7 D011725
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 78371, Olomouc, Czech Republic
- 700 1_
- $a Vanda, David $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic
- 700 1_
- $a Soural, Miroslav $u Department of Organic Chemistry, Faculty of Science, Palacký University, 17. Listopadu 12, 77146, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900, Olomouc, Czech Republic. Electronic address: miroslav.soural@upol.cz
- 700 1_
- $a Kryštof, Vladimír $u Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany, The Czech Academy of Sciences, Šlechtitelů 27, 78371, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900, Olomouc, Czech Republic. Electronic address: vladimir.krystof@upol.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 211, č. - (2021), s. 113094
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33340912 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100844 $b ABA008
- 999 __
- $a ok $b bmc $g 1690166 $s 1139721
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 211 $c - $d 113094 $e 20201209 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- GRA __
- $a NV17-31834A $p MZ0
- LZP __
- $a Pubmed-20210728